Hospitals Immunity Inpatient 
ALiEM - Pharm Pearls
MARCH 29, 2023
The goal remains to identify infants with bacterial infections in this at-risk cohort of patients while also considering the balance of cost-effectiveness on a population scale and the potential for iatrogenic harm with evaluation such as unnecessary lumbar punctures, unnecessary antibiotics, and unnecessary hospitalization. No LP needed.
Pharmacy Joe
OCTOBER 18, 2023
In this episode, I’ll discuss why hypokalemia can result from digoxin immune fab fragment administration. With the administration of antidote therapy with digoxin immune fab fragments, the function of the sodium-potassium ATPase pump is restored.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Joe
OCTOBER 18, 2023
In this episode, I’ll discuss why hypokalemia can result from digoxin immune fab fragment administration. With the administration of antidote therapy with digoxin immune fab fragments, the function of the sodium-potassium ATPase pump is restored.
RX Note
AUGUST 4, 2023
What can I expect once I entered hospital provisional registered pharmacist training? In most hospitals, you first introduction to your workplace is through an induction period during which you are shown many different areas and meet many new people. What to do if I did not know the answer to questions from patients or doctors?
Pharmacy Joe
DECEMBER 18, 2024
The most common causes of acute liver failure were: viral hepatitis, drug-induced (but not from acetaminophen), auto-immune hepatitis and cause indeterminate. Treatment also was responsible for a lower length of hospital stay when compared to control. The relative risk in favor of treatment was 0.56.
Pharmacy Joe
FEBRUARY 10, 2021
In this episode, I’ll discuss why hypokalemia can result from digoxin immune fab fragment administration. With the administration of antidote therapy with digoxin immune fab fragments, the function of the sodium-potassium ATPase pump is restored.
Pharmaceutical Technology
OCTOBER 6, 2022
BioLink Life Sciences has received a contract worth $750,000 from the US Biomedical Advanced Research and Development Authority (BARDA) to develop Ramatroban for treating Covid-19 pneumonia patients in the hospital setting. Ramatroban will be analysed in a placebo-controlled, randomised Phase II/III RAMBAN-1 clinical trial.
Expert insights. Personalized for you.
360 
Let's personalize your content